Revenue/Profit Under Pressure Amid Channel Destocking
发布时间:2026-10-27 来源:华泰证券
China Resources Jiangzhong Pharma has reported 9M26 revenue of RMB2.66bn,attributable net profit of RMB620mn,and recurring net profit of RMB590mn,down 9.2/9.7/7.9%YoY.For 3Q26,revenue was RMB730mn,attributable net profit RMB130mn,and recurring net profit RMB120mn,down 7.9/21.8/24.3%YoY.We expect revenue and profit to return to growth for the full year as channel inventory normalizes.As aleading OTC gastrointestinal drugmaker in China,the company continues to strengthen academic promotion and improve channel operating efficiency.We expect it to gradually return to agrowth trajectory.Maintain BUY.
OTC/prescription drugs soft;health consumer products steady
For 9M26,revenue remained under pressure.1)OTC revenue was RMB1.90bn,down 9%YoY.Demand for Jianwei Xiaoshi Pian stayed stable with steady sell-through.Bifid Triple Viable Capsules sales volume was stable,though revenue declined on VAT rate changes.Lactic acid bacteria tablet sell-through was steady,and channel inventory fell notably.2)Prescription drug revenue was RMB430mn,down 25%YoY,mainly due to broader volume-based procurement(VBP),medical insurance cost controls,and changes in the hospital promotion environment.Health consumer product revenue was RMB340mn,up 2%YoY.The company strengthened online promotion and e-commerce operations for key products such as Shenlingcao,Chuyuan,probiotics,and Gan Chun,improving sales conversion efficiency.
Gross margin declined but receivables and inventory down
1)For 9M26,gross margin was 65.7%,down 0.3pp YoY,mainly as the company proactively controlled shipment pace,lowering the revenue mix of some high-margin and core products.2)The 9M26 selling/administrative/R&D expense ratios were 29.7/5.4/2.6%,down 0.4pp/up 0.8pp/down 0.7pp YoY.The lower selling expense ratio reflected refined cost control;the higher administrative expense ratio was due to lower revenue;and the lower R&D expense ratio came from optimized R&D spending.Cash flow was solid:9M26 cash received from goods sales was RMB3.40bn,about 128%of revenue,and net operating cash flow was RMB1.00bn,about 162%of net profit.Notes receivable,accounts receivable,and receivables financing fell by RMB300mn from the start of the year to RMB550mn.Inventory fell RMB10mn from the start of the year to RMB440mn.Channel destocking drove marginal balance sheet improvement.
15th FYP largely complete;finalization expected in 4Q26
2025 marks the final year of the company’s 14th Five-Year Plan(FYP).The company has completed its strategic review of the 14th FYP and held apreliminary seminar on the 15th FYP.Under China Resources Group's guidance,the company has apreliminary plan for the 15th FYP period and is refining its approach and key modules to build consensus.We expect the 15th FYP to be finalized in 4Q26.
Earnings forecasts and valuation
We maintain our earnings forecasts.We expect 2026/2027/2028 attributable net profit of RMB1.00/1.15/1.23bn,up 10/15/8%YoY.We apply a2026E PE of 20x,a premium to the peer average of 19x on Wind consensus,reflecting the company's operating resilience amid the OTC industry downturn.Our target price is RMB31.40(previous:RMB30.25,based on 19x 2026E PE and RMB1.00bn profit;the change mainly reflects higher peer valuations).Maintain BUY.
Risks:weaker OTC drug demand than we expect,policy risks in the traditional Chinese medicine industry than we expect,and raw material price fluctuations.